BioAffinity Technologies (BIAF) announced that the Australian Patent Office has accepted a patent application for the company’s proprietary platform technology for assessing lung health and predicting the likelihood of multiple lung diseases in patients. The patent application covers methods that use flow cytometry combined with fluorescent probes, molecular “tags” that attach to specific cell types, to detect cellular and molecular signatures of multiple lung diseases.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BIAF:
- bioAffinity Technologies Secures Australian Patent for Lung Health
- bioAffinity Technologies Advances Non-Invasive Lung Cancer Diagnostic Study
- bioAffinity Technologies Advances Lung Cancer Detection with Innovative Study
- bioAffinity Technologies Presents at CHEST 2025 Conference
- bioAffinity Technologies Secures Patent for Lung Cancer Detection